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■ LETTER TO THE EDITOR ■
Treatment of patients with advanced ovarian cancer
mainly involves aggressive cytoreductive surgery and
administering adjuvant chemotherapy with carboplatin
and paclitaxel. Carboplatin is metabolized by the kidney,
and thus, a diminished dose of carboplatin is consid-
ered for patients with chronic renal failure to prevent
further renal impairment resulting in secondary com-
plications, such as anemia, hypertension, and throm-
bocytopenia [1,2]. Paclitaxel is metabolized by the liver,
and less than 10% of the metabolite is eliminated renally
[3]. So, we are able to administer a full dose of paclitaxel
in renal insufficient patients, since its elimination does
not depend on renal clearance [2]. Here, we present
the course of treatment of a patient with advanced
ovarian cancer who was receiving hemodialysis.
A woman aged 69, gravida 2, para 2, had suffered
from glaucoma for 12 years and chronic nephritis for
10 years and was receiving hemodialysis three times a
week. The patient attended hospital because of the
lower abdominal pain she had suffered for 4 months.
Pelvic ultrasonography revealed a right adnexal tumor
12 × 10 × 9 cm in size and a left adnexal tumor 5.4 ×
3.2 × 3 cm in size, which were partly solid and had an
irregular septum. Multiple enlarged right axillary lymph
nodes were also found. In addition to the aforemen-
tioned findings, pelvic computed tomography scan
revealed an omental lesion. Laboratory findings were
as follows: 1,603 U/mL CA125, 95 mg/dL blood urea
nitrogen (BUN), and 7.7 mg/mL creatinine. Transperi-
toneal laparotomy confirmed that the bilateral ovarian
tumor had invaded the bilateral fallopian tubes and the
surface of the uterus and had metastasized to the greater
omentum and peritoneum. The patient underwent
total hysterectomy, bilateral salpingo-oophorectomy,
omentectomy, pelvic lymphadenectomy, and right axil-
lary lymphadenectomy. Pathologic findings indicated
undifferentiated papillary serous adenocarcinoma. Pelvic
lymph nodes were unaffected, but right axillary lymph
nodes were affected by serous adenocarcinoma. The
patient was diagnosed with stage IV ovarian cancer,
according to the International Federation of Gynecology
and Obstetrics (FIGO) staging system.
After surgery, the patient was treated with carbo-
platin and paclitaxel. The dose (mg) of carboplatin used
was AUC × (GFR + 25), according to the Calvert for-
mula [4,5]. The area under the concentration-time curve
(AUC) was administered at 5 mg/mL, with a glomeru-
lar filtration rate (GFR) of zero. Hence, the dose of
carboplatin used was 125 mg (5 × 25), and the dose of
paclitaxel used was 135 mg/m2. However, after the
first course of chemotherapy, the patient experienced
pancytopenia, with white blood count decreasing to
1,300/mm3, hemoglobin to 7.5 g/dL and platelet count
to 2,100/mm3. After supportive treatment, the blood
count became normal again. In the second course of
chemotherapy, the dose of carboplatin was reduced to
80 mg and paclitaxel to 90 mg/m2. Then, the patient
followed the reduced dosing schedule for the remaining
five courses without occurrence of severe bone marrow
suppression. After the fourth course of chemotherapy,
the CA125 had decreased to 15 U/mL, and the patient
was fine. However, after 3 months of completion of
chemotherapy, the patient died of acute myocardial
infarction suddenly without any signs of relapse.
Treating ovarian cancer with first-generation plat-
inum, such as cisplatin, is often complicated by renal
dysfunction, neurotoxicity, and severe vomiting. These
side effects are less common in the second-generation
platinum analogue carboplatin, but carboplatin causes
bone marrow suppression and particularly decreases
platelet count. At present, carboplatin combined with
paclitaxel is the most acceptable first-line chemotherapy
for ovarian cancer.
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For patients diagnosed with ovarian cancer and
receiving hemodialysis, a lower dose of carboplatin is
still effective, because carboplatin is metabolized to a
lesser extent in this situation. Approximately 65% to 75%
of carboplatin is excreted in the urine. In the human
body, carboplatin has a half-life of 2 to 6 hours in nor-
mal kidney function, but carboplatin has a half-life of
13–16 hours in renal failure [6]. Approximately 25% of
carboplatin is removed by irreversible protein binding
and hepatic metabolism [2]. Only 15% to 20% of carbo-
platin is removed by hemodialysis. Accordingly, carbo-
platin administered to patients with chronic renal failure
must be low-dose; otherwise, carboplatin would cause
enhanced toxicity and side effects to the patients.
The dosage of most anticancer drugs is calculated
by body surface area (BSA). An average person has a
BSA of 1.5, as indicated by the point of intersection
between the linear functions of body height (cm) and
body weight (kg). For instance, a patient receiving car-
boplatin for 3 weeks at a rate of 300–400 mg/m2 has to
be administered with approximate 450–600 mg dose of
carboplatin (1.5 × 300–400 = 450–600 mg). The afore-
mentioned dosage is too high for patients with renal
failure and causes severe side effects in the patients,
because carboplatin is mostly metabolized by the kid-
neys. The suggested dose (mg) is AUC (mg/mL) ×
(GFR + 25), according to the Calvert formula, where
AUC denotes the area under the concentration-time
curve and GFR denotes glomerular filtration rate [5].
Carboplatin is usually administered to previously treated
patients at AUC of 4–6 mg/mL and chemotherapy-naïve
patients at AUC of 5–7.5 mg/mL.
In our case, the GFR was zero, and thus, the car-
boplatin clearance was 25 mL/min (GFR + 25 = 0 +
25 = 25). With an AUC of 5 mg/mL, the dosage of car-
boplatin used was 5 × 25 mg = 125 mg. After receiving
the aforementioned dose for one course of chemo-
therapy, the patient experienced severe pancytopenia
and, therefore, needed a rest and transfusion. Then,
the dose of carboplatin was reduced to 80 mg, and the
dose of paclitaxel was decreased from 135 mg/m2 to
90 mg/m2, in order to proceed with chemotherapy
without pancytopenia.
Jeyabalan et al [7] reported administering 125 mg
of carboplatin and 175 mg/m2 (total of 298 mg) of
paclitaxel for six courses after surgery to a patient diag-
nosed with staged III ovarian cancer complicated by
renal failure. The chemotherapy caused numbness to
the patient’s fingers but did not decrease the platelet
count, and the patient was fine at 11 months after
commencement of chemotherapy. Hence, the required
dosage adjustment of carboplatin for patients diag-
nosed with ovarian cancer complicated by renal failure
seems to differ from person to person; hopefully, more
upcoming cases can give us an insight into the issue.
Our case had CA125 returning to a normal level, and
the patient had complete response by the time the
fourth course of chemotherapy ended. Unfortunately,
the patient suddenly died of heart disease after 3
months of chemotherapy, thus raising questions about
the course of chemotherapy. The possibility of pacli-
taxel inducing cardiomyopathy was less likely, because
myocardial infarction is seen only during and not over
14 days following paclitaxel therapy [8].
Watanabe et al [3] reported of a woman with ovar-
ian cancer and chronic renal failure on hemodialysis
who was treated with carboplatin/paclitaxel combina-
tion chemotherapy after surgery. Paclitaxel was admin-
istered at 150 mg/m2, and carboplatin was chosen to
produce a target AUC of 5 mg/mL. Hemodialysis was
started 1.5 and 16 hours after the end of carboplatin
administration in the first and second course of
chemotherapy, respectively. The pharmacokinetic studies
showed that the AUCs of free platinum and paclitaxel
were 2.21 µg-min/mL and 16.3 µg-h/mL, respectively, in
the first course, and 4.43µg-min/mL and 15.9µg-h/mL,
respectively, in the second course. These values were
comparable to those analyzed by pharmacokinetic stud-
ies in patients with normal renal function previously
[9–11]. Therefore, when carboplatin was administered
with AUC of 5 mg/mL, as well as a similar dose of
paclitaxel on hemodialysis, they were able to produce
good tumor response.
In summary, it is feasible to administer carboplatin
and paclitaxel concurrently to patients with ovarian can-
cer who are receiving hemodialysis, though a lower-dose
chemotherapy is recommended, especially a lower dose
of carboplatin. The chemotherapy can start with 125 mg
of carboplatin, and the carboplatin dose should be
reduced in the case of severe bone marrow suppression.
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